Our discovery platform enables us to develop best-in-class therapeutic antibodies in auto-immune and inflammatory disease.
Monoclonal antibodies have proven to be efficacious in several inflammatory and immune diseases, including rheumatoid arthritis, inflammatory bowel disease and psoriasis, commonly targeting cytokines, receptors, and other signalling molecules.
We are determined to exploit the strength of our antibody discovery platform to deliver a new generation of therapeutic antibodies that tackle inflammatory disorders, which continue to represent a high level of unmet clinical need.
Among our projects are lead antibody therapeutics against OX40L, which is expressed on antigen-presenting cells and activates T-cells through binding its receptor OX40. We are developing this product for T-cell driven inflammatory diseases.
We announced positive data in our Phase I trial of our fully human monoclonal antibody KY1005. The results from the Phase I study demonstrated that KY1005 had a favourable safety profile and was well tolerated. In addition, KY1005 was shown to block T-cell-driven inflammation in the skin of healthy volunteers. The study was a single and multiple ascending-dose, placebo-controlled, double-blind, Phase I study in 64 healthy volunteers.
KY1005 will now proceed to Phase II studies in atopic dermatitis in 2018, with additional plans to run studies in other immune-mediated diseases, such as Graft-versus-Host Disease (GvHD).